Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Claude Tardif

Showing results (1-10 of 744) with videos related to

Pageof 75
Sort By:
The American Journal of Cardiology|March 21, 2003
Clinical results with AGI-1067: a novel antioxidant vascular protectantJean-Claude Tardif
Current Atherosclerosis Reports|February 3, 2005
Antioxidants and atherosclerosis: emerging drug therapiesJean-Claude Tardif
Drugs|December 6, 2007
Clinical results of I(f) current inhibition by ivabradineJean-Claude Tardif
Journal of Clinical Lipidology|December 3, 2010
Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology?Jean-Claude Tardif
British Medical Bulletin|May 29, 2009
Heart rate as a treatable cardiovascular risk factorJean-Claude Tardif
The Canadian Journal of Cardiology|February 25, 2006
Antioxidants: the good, the bad and the uglyJean-Claude Tardif
The Canadian Journal of Cardiology|October 20, 2005
Atherosclerosis imagingJean-Claude Tardif
The Canadian Journal of Cardiology|February 18, 2006
Cardiac investigation in patients with diabetesJean-Claude Tardif
Drugs of Today (Barcelona, Spain : 1998)|June 10, 2008
Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseasesJean-Claude Tardif
The Canadian Journal of Cardiology|August 25, 2006
Prevention challenges: the era of atherosclerosis regressionJean-Claude Tardif
Pageof 75

Showing results (1-10 of 744) with videos related to

Sort By:
Pageof 75
The American Journal of Cardiology|March 21, 2003
Clinical results with AGI-1067: a novel antioxidant vascular protectantJean-Claude Tardif
Current Atherosclerosis Reports|February 3, 2005
Antioxidants and atherosclerosis: emerging drug therapiesJean-Claude Tardif
Drugs|December 6, 2007
Clinical results of I(f) current inhibition by ivabradineJean-Claude Tardif
Journal of Clinical Lipidology|December 3, 2010
Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology?Jean-Claude Tardif
British Medical Bulletin|May 29, 2009
Heart rate as a treatable cardiovascular risk factorJean-Claude Tardif
The Canadian Journal of Cardiology|February 25, 2006
Antioxidants: the good, the bad and the uglyJean-Claude Tardif
The Canadian Journal of Cardiology|October 20, 2005
Atherosclerosis imagingJean-Claude Tardif
The Canadian Journal of Cardiology|February 18, 2006
Cardiac investigation in patients with diabetesJean-Claude Tardif
Drugs of Today (Barcelona, Spain : 1998)|June 10, 2008
Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseasesJean-Claude Tardif
The Canadian Journal of Cardiology|August 25, 2006
Prevention challenges: the era of atherosclerosis regressionJean-Claude Tardif
Pageof 75